BRISTOL MYERS SQUIBB CO BMY

Latest FY: 2025 Healthcare Drug Manufacturers - General
Market Price $63.84
Market Cap $132.02B
P/E Ratio 18.45
Quick Peer Compare (Healthcare):
Revenue (FY 2025) ↓-0.2% YoY
$48.19B
3-Yr CAGR: 1.4%
Net Income ↑178.8% YoY
$7.05B
Net Margin: 14.6%
Free Cash Flow ↓-7.9% YoY
$12.85B
FCF Yield: 9.73%
EPS (Diluted) ↑178.5% YoY
$3.46
Basic: $3.47
Return on Equity Efficiency
38.2%
ROA: 7.8%

📊 Multi-Year Historical Performance & Trends

Financial Performance History Revenue, Net Income & Free Cash Flow
Margins Trend (%) Gross, Operating & Net Margins
Balance Sheet Strength Cash, Debt & Equity
Cash Flow Generation Operating Cash Flow vs CapEx vs FCF

📈 Year-over-Year (YoY) Growth History (BMY)

All monetary values in millions ($M)
Fiscal Year Revenue Revenue YoY Gross Profit Net Income Net Inc YoY Diluted EPS EPS YoY Op. Cash Flow Free Cash Flow FCF YoY
FY 2016 $19,427.0M $14,481.0M $4,457.0M $2.65 $2,850.0M $1,635.0M
FY 2017 $20,776.0M +6.9% $14,710.0M $1,007.0M -77.4% $0.61 -77.0% $5,275.0M $4,220.0M +158.1%
FY 2018 $22,561.0M +8.6% $16,014.0M $4,920.0M +388.6% $3.01 +393.4% $5,940.0M $4,989.0M +18.2%
FY 2019 $26,145.0M +15.9% $18,067.0M $3,439.0M -30.1% $2.01 -33.2% $8,067.0M $7,231.0M +44.9%
FY 2020 $42,518.0M +62.6% $30,745.0M $-9,015.0M -362.1% $-3.99 -298.5% $14,052.0M $13,299.0M +83.9%
FY 2021 $46,385.0M +9.1% $36,445.0M $6,994.0M +177.6% $3.12 +178.2% $16,207.0M $15,234.0M +14.5%
FY 2022 $46,159.0M -0.5% $36,022.0M $6,327.0M -9.5% $2.95 -5.4% $13,066.0M $11,948.0M -21.6%
FY 2023 $45,006.0M -2.5% $34,313.0M $8,025.0M +26.8% $3.86 +30.8% $13,860.0M $12,651.0M +5.9%
FY 2024 $48,300.0M +7.3% $34,332.0M $-8,948.0M -211.5% $-4.41 -214.2% $15,190.0M $13,942.0M +10.2%
FY 2025 $48,194.0M -0.2% $34,258.0M $7,054.0M +178.8% $3.46 +178.5% $14,156.0M $12,845.0M -7.9%
$

Valuation

Market Price $63.84
Market Cap $132.02B
Enterprise Value $166.64B
P/E Ratio 18.45
P/B Ratio 7.06
FCF Yield 9.73%
Dividend Yield 3.90%
Shares Outstanding 2,042,071,200
%

Profitability & Margins

Gross Margin 71.08%
Operating Margin 1.40%
Net Margin 14.64%
Return on Equity (ROE) 38.19%
Return on Assets (ROA) 7.83%
Asset Turnover 0.54x
Revenue 3-Yr CAGR 1.45%
🛡️

Financial Health & Liquidity

Current Ratio 1.26
Cash Ratio 0.44
Debt / Equity 2.427
Debt / Assets 0.498
Cash & Equivalents $10.21B
Total Debt $44.83B
Book Value / Share $9.05
💧

Cash Flow Efficiency

Operating Cash Flow $14.16B
Capital Expenditures (CapEx) $1.31B
Free Cash Flow $12.85B
OCF / Revenue 29.37%
FCF / Revenue 26.65%
FCF 3-Yr CAGR 2.44%
🏷️

Per Share Metrics

EPS (Diluted) $3.46
EPS (Basic) $3.47
Dividends / Share $2.49
Book Value / Share $9.05
EPS YoY Growth 178.46%
🏛️

Balance Sheet (FY 2025)

Total Assets $90.04B
Total Liabilities $71.53B
Stockholders' Equity $18.47B
Current Assets $29.39B
Current Liabilities $23.42B